



NeuroVista Receives Approval for Expanding Australian Clinical Study

Seattle, WA—February 1, 2011—NeuroVista Corporation, a developer of innovative medical technologies for the management and treatment of epilepsy, today announced approval for expanding patient enrollment in their clinical study to evaluate the safety and effectiveness of the NeuroVista[®] Seizure Advisory System[™] in patients with medically refractory epilepsy.

A total of 10 subjects have been implanted with the NeuroVista Seizure Advisory System at three medical centers in Melbourne, Australia. Based upon initial positive clinical results the Human Research Ethics Committees at St. Vincent's Hospital, Austin Hospital and the Royal Melbourne Hospital have approved an expansion of the study to include an additional five subjects who will receive the NeuroVista system. Uncertainty about when seizures are going to strike has been identified as a leading cause of disability for people living with medically refractory epilepsy. Seizure advisory information is intended to enable people living with epilepsy to reduce injuries and engage more fully and confidently in daily activities.

“The NeuroVista Seizure Advisory System is the first medical device with the potential of advising the likelihood of seizure,” said John F. Harris, President and Chief Executive Officer of NeuroVista. “We are pleased that initial clinical data of safety and effectiveness supports an expansion of the study. We look forward to the continued collaboration with our clinical investigators in Melbourne, and firmly believe our technology has the potential to significantly improve the management of epilepsy.”

“In addition to its potential for seizure prediction, the chronic high quality intracranial EEG recordings provide a highly accurate method of monitoring the effect of treatment changes on seizure frequency in patients who are not always aware of when they have had a seizure, said Dr. Terry O'Brien, Royal Melbourne Hospital.”

About NeuroVista

NeuroVista is a clinical stage medical device company pioneering new technologies that will revolutionize the management and treatment of epilepsy. Epilepsy is a neurological condition affecting approximately 1% of the U.S. population—more than Parkinson's disease, multiple sclerosis, and Lou Gehrig's disease combined. NeuroVista is a privately held company based in Seattle. For more information, visit www.neurovista.com.